AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05934916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP ( Continuous positive airway pressure)
Description: The enrolled eighty patients were simply randomized into two equal groups: Non-CPAP group and CPAP group using a computer-generated table of random numbers. The group allocation was concealed in sequentially numbered, sealed, and opaque envelopes. Patients were selected from isolation center in Mansoura University hospital,Non-CPAP group will receive medical treatment plus oxygen therapy according to recommendation of protocol of the Egyptian Ministry of Health 2020 and CPAP group as in Non-CPAP group plus using CPAP.
Study NCT05934916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Description: both groups will receive oxygen
Study NCT05978518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPM Device + Monitoring
Description: Daily device use \& data monitoring leading to symptomology assessment and notification to provider.
Study NCT05978518 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: CPM Device
Description: Daily device use
Study NCT04861844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness training
Description: phone based mindfulness training on 4 consecutive days
Study NCT04861844 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active listening
Description: The active listening intervention script asks the participant to attend by relaxing their body and visualizing themself in various exotic locations and narratives described in the script; it also asks the participant to rate their attention level of various points. The active listening scripts were compiled from National Geographic article excerpts (taken from the public domain)
Study NCT06366646 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Competency-based intervention
Description: 90 head nurses and their assistants received the competency-based intervention program
Study NCT05843292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxane and Carboplatin
Description: Nab-paclitaxel 100mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.~or Docetaxel 75mg/m2+ Carboplatin AUC5 by intravenous (IV) infusion on day1, every 3 weeks, for 4 cycles.~or Paclitaxel 80mg/m2+ Carboplatin AUC2 by intravenous (IV) infusion on day1, day8 and day15, every 4 weeks, for 4 cycles.
Study NCT05843292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-term Sintilimab
Description: Sintilimab 200mg by intravenous (IV) infusion on day1, every 3 weeks, for 2 cycles.
Study NCT05843292 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
Study NCT06064058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ghazwan program
Description: 6-month lifestyle modification program, focusing on diet, sleep, exercise, and vitamin D and magnesium correction.
Study NCT06064058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard management
Description: Standard care with NSAIDs and acetaminophen for pain management
Study NCT05682547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Diquafosol tetrasodium
Description: 3% Diquafosol tetrasodium eye drops will be used to assess its usefulness in diabetic dry eye symptoms
Study NCT05682547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% hyaluronate
Description: 0.1% hyaluronate eye drops will be used to assess its usefulness in diabetic dry eye symptoms and compared to 3% Diquafosol tetrasodium eye drops.
Study NCT04606901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine/glycopyrrolate
Description: neuromuscular blockade reversal agents
Study NCT04606901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: neuromuscular blockade reversal agent
Study NCT05634148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
Study NCT05634148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine will be administered 45 minutes before extubation in intervention group
Study NCT06026241 — intervention group
Intervention type: OTHER
Intervention: Collecting data from the medical record
Description: Patient's socio-demographic data (age, gender, residence), comorbidities, cause of death, date and frequency of care measures/treatments/paraclinical exams received before their death.
Study NCT05137717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir tablets
Study NCT06018805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMI≥30; Combined Spinal Epidural Anesthesia
Description: Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration ( in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
Study NCT06018805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMI:18,5-24,9; Combined Spinal Epidural Anesthesia
Description: Combined epidural spinal anesthesia will be performed with the loss of resistance method at constant volume and concentration in both patient groups. For QT interval measurements, ECG recordings will be taken before spinal anesthesia, 5 and 30 minutes after the block, and 60 and 120 minutes postoperatively.
Study NCT04678505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3402
Description: MK-3402 administered as a single dose of 100 mg IV infusion on the following dosage days:~Panels A to D: Day 1 Panel E: Day 1 in Periods 1 and 2
Study NCT04978324 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: leukocyte platelet rich fibrin (L-PRF)
Description: Participants blood will be spun to obtain L-PRF strips and liquid L-PRF. Pockets will receive insertion of small L-PRF strips followed by liquid L-PRF injections to fill the 5-8mm pockets of the test side.
Study NCT04978324 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Scaling and root planing, which is the standard of care, will be performed on the control side using Cavitron and hand scalers on test and control sides under local anesthesia.
Study NCT05543538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimedia audio-visual program
Description: Participants in the control group will receive teaching method with multimedia audio-visual material.
Study NCT05543538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: multimedia audio-visual program
Description: Participants in the control group will receive teaching method with multimedia audio-visual material.
Study NCT05543538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experiential learning programmes
Description: Participants in the experimental group will receive teaching method with experiential learning.
Study NCT05543538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: teachers' personal demonstration
Description: Participants in the experience group will receive teachers' personal demonstration.
Study NCT05922644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS
Description: 21 days of cervical spinal cord electrical stimulation treatment in addition to routine brain resuscitation and rehabilitation awakening treatment.
Study NCT05922644 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Routine brain resuscitation and rehabilitation awakening treatment.
Study NCT05270980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cohorting
Description: The cohorting strategy will result in pairing serology-positive staff with serology-negative residents and serology-negative staff and serology-positive residents to the degree that penetration of serologic presumed immunity allows this pairing to be positive. Any resident who refuses serology testing will be treated as if they are serology negative as the safest strategy for risk of unwanted exposure.
Study NCT05460949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOLD RELAX STRETCHING OF ILIOPSOAS
Description: 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~• The stretching exercise was performed 2 times a week for 8 weeks. 10 second isometric contraction of iliopsoas muscle (HR), 10-second rest, 20 second static stretch, 5 repetitions.~The stretching exercise was performed 2 times a week for 8 weeks.
Study NCT05460949 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WILLIAM'S PROTOCOL
Description: Pelvic tilt Single Knee to chest Double knee to chest Partial sit-up Hamstring stretch Hip Flexor stretch Squat Each group performed special trainings for 8 weeks, 2 sessions per week; each session took about 1 hour. Duration of each exercise was 8 to 10 seconds in each set. Protocols were started with 1 set of 10 repetitions at starting baseline and by improving performance and patients' compatibility with trainings, all eventually finished with 3 sets of 20 repetitions at the end of protocols.
Study NCT04987463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin in capsules administered orally, initially (between V1 and V2) once daily in the evening,and starting from V2 administered two times daily.
Study NCT04987463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin in liquid administered orally, in the morning, every other day or daily depending on the patient's body weight. The starting dose of rapamycin will be calculated according to the body weight of the patient measured at V1.
Study NCT04987463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in liquid administered orally, once daily, in the morning. The starting dose of placebo in liquid will be calculated according to the body weight of the patient measured at V1.
Study NCT04987463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo in granules administered orally, initially once daily in the evening,and after reaching the targeted dose administered two times daily.
Study NCT03870334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BT-11 880 mg
Description: Oral once daily tablet
Study NCT03870334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral once daily tablet
Study NCT05130827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plinabulin
Description: 40mg flat dose IV infusion, infused over approximately 30 minutes starting between 1-3 hours after stem cell infusion on day 0.
Study NCT04833777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetics Lidocaine
Description: 10 mL 1% lidocaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
Study NCT04833777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Anesthetics Bupivacaine
Description: 5 mL 1% lidocaine with 1:100,000 epinephrine + 5 mL 0.5% bupivacaine with 1:100,000 epinephrine and 1 mL 8.4% sodium bicarbonate
Study NCT04716972 — intervention group
Intervention type: OTHER
Intervention: survey
Description: Online survey
Study NCT04716972 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interview
Study NCT05722730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pilates Exercises
Description: The intervention group will perform an exercise protocol based on the Pilates method, by a physiotherapist specialized in Pilates and independent of the researchers, using the method's own equipment, with a frequency of 2x/week, for 12 weeks in therapeutic sessions of identical protocols lasting 60 min.
Study NCT05504837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KB407 (Nebulization)
Description: Nebulized solution of KB407, a replication-defective HSV-1 expressing full length human CFTR
Study NCT06203509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thrive Intervention
Description: • The THRIVE Clinical Pathway is a standardized transitional care clinical pathway that supports Medicaid insured or Medicaid eligible individuals being managed for both chronic diseases and serious mental illness following hospitalization.
Study NCT05862493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FOCUS echocardiography
Description: Preoperative FOCUS echocardiography. Based on FOCUS information: correction of low level of venous return and/or step-up monitoring and/or vasoactive drugs
Study NCT05262816 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: electroacupuncture at Sanyinjiao (SP6)
Study NCT05262816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: electroacupuncture at Sanyinjiao (SP6)
Study NCT05947604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acoziborole
Description: Acoziborole 960 mg (three tablets of 320 mg) for oral route in fasted condition Period 2: single oral administration on Day 12
Study NCT05947604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: • Midazolam 5 mg syrup in fasted condition Period 1: Single oral dose of 5 mg administered on Day 8 Period 2: Single oral dose of 5 mg administered on Day 21
Study NCT05947604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dextromethorphan
Description: • Dextromethorphan 15 mg syrup in fasted condition Period 1: Single oral dose of 15 mg administered on Day 1 Period 2: Single oral dose of 15 mg administered on Day 14
Study NCT05743153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal intervention program
Description: Exercise intervention: combined endurance and resistance training three times a week using workout video's which patients can do at home. Advice to exercise at low-intensity for at least 30 minutes per day.~Nutritional intervention: Patients are advised to aim for optimal energy and protein intake (by registered dietician) and to avoid red meat, processed foods and sweetened drinks. Aiming for a mainly plant based diet.~Psychological intervention: screening for psychological risk factors and if present, patients are referred to a psychologist for psychological support.
Study NCT05881655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airdoc Red Lighting Device
Description: A medical device with ultra low lever laser irradiance of 0.6mW or 1.2mW at the surface of cornea. And the therapy lasts 3 minutes with the 4 hours or more interval of break.
Study NCT05881655 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Special Spectacles to Control Myopia
Description: Customer designed power and fitting to each subject for all the study periods.
Study NCT05881655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Special Spectacles to Control Myopia
Description: Customer designed power and fitting to each subject for all the study periods.
Study NCT06136468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual coach
Description: The virtual coch will be displayed to the participants using an optical see-through head-mounted display
Study NCT00662077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Ibandronate endovenous 3 mg every 3 months
Study NCT00662077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modifications
Description: Lifestyle modifications: counseling every 3 months
Study NCT00662077 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle modifications
Description: Lifestyle modifications: counseling every 3 months
Study NCT05864534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Balstilimab 450 mg IV over 30 minutes every 3 weeks
Study NCT05864534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Botensilimab1mg/kg mg IV over 30 minutes every 6 weeks
Study NCT05864534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks
Study NCT05864534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonocloud-9 (SC-9)
Description: Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks
Study NCT04753294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo NPWT System
Description: Wound treatment with Avance Solo NPWT System for up to 28 days.
Study NCT04753294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avance Solo Adapt NPWT System
Description: Wound treatment with Avance Solo Adapt NPWT System for up to 28 days.
Study NCT05201846 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIA:CONN G8 insulin pump
Description: Subjects on continuous subcutaneous insulin infusion system with CGM
Study NCT05201846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple daily insulin injection
Description: Subjects on multiple daily insulin injection with CGM
Study NCT04987112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN1012
Description: CAN1012 IT injection (once every 4 weeks)
Study NCT05051046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy under hypnosis
Description: The hypnosis used will be of the Ericksonian type. Before the colonoscopy begins, the IDE puts the patient in a hypnotic situation.
Study NCT05465369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: giomer
Description: injectable flowable Giomer composites is a material used for direct filling techniques has been developed over the past years. It has the property of Giomer technology that able to release and recharge fluoride and other beneficial ions for the life of the restoration and induce remineralization of the underlying hard dental tissues . Injectable flowable Giomer composite (Beautifil flow plus x) has a long-term clinical performance like conventional composite., it also aids in decrease acid production and formation of antiacid resistant layer, help in reduction of tooth mineral solubility also it has high survival rate and wear resistance in high stress bearing areas in posterior teeth Beautifil Flow Plus X also helps to remineralise the tooth structure for sustainable caries prevention and easily polishes for long-lasting luster
Study NCT05465369 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high viscosity glass ionomer
Description: High viscous glass ionomer, the most suitable restorative material for ART procedure and can be used outside the dental clinic, which increases the opportunity for dental care , using a high-viscosity glass-ionomer as an ART sealant in both primary and permanent posterior teeth have a high caries preventive effect High viscosity glass ionomer (EQUIA Fil) has new technology involves ultrafine, and highly reactive glass diffused within the glass-ionomer fillers to increase and enhance matrix formation. This system allows ion availability and builds a stronger matrix structure with greater physical properties, wear resistance and fluoride release. Mechanical properties and fluoride release is the most important features to evaluate glass ionomer restorative material and it's proven that EQUIA Fil fulfilled all these requirement
Study NCT04860479 — intervention group
Intervention type: DEVICE
Intervention: ultrasound
Description: ultrasonography to inguinal region
Study NCT05262335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Oxaliplatin + Capecitabine
Description: 1. Before 6 cycles, Anlotinib 12mg, po.qd, d1-14; Capecitabine 850 mg/m2, po. bid, d1-14; Oxaliplatin 130 mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study NCT05262335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Cisplatin + Paclitaxel/ Docetaxel
Description: 1. Anlotinib 12mg, po.qd, d1-14; Cisplatin 60-75mg/m2, iv, d1/d1-d3; Paclitaxel 135mg/m2, iv (D1). or Docetaxel 75mg/m2, iv (D1). The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study NCT05262335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib + Standard first-line chemotherapy
Description: 1. Anlotinib 12mg, po.qd, d1-14; Standard first-line chemotherapy determined by the researchers. The above schemes are repeated every three weeks.~2. After 6 cycles, the regimen is changed to Anlotinib (12mg, po.qd, d1-14)+ Capecitabine (500 mg, po. bid, d1-21). The regimen is repeated every 3 weeks until the disease progresses or unacceptable toxicity.
Study NCT04613518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Specified Dose on Specified Days
Study NCT04613518 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Specified Dose on Specified Days